Dyno Therapeutics, Inc. came out of stealth mode a year ago with $9m in seed funding it raised in 2018 and partnerships with Novartis AG and Sarepta Therapeutics, Inc. worth more than $2bn in upfront, research and milestone fees to create novel adeno-associated viral (AAV) vectors for the delivery of gene therapies. The seed money and upfront fees were expected to fund development of Dyno’s CapsidMap platform for a few years, but the company unveiled a $100m series A venture capital round on 6 May to further accelerate its use of artificial intelligence to design novel AAV vectors.
“We've been well funded since the beginning of the company,” CEO Eric Kelsic told Scrip
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?